利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.028 秒)

    Removal promoters and inhibitor for apoptosis cells in vivo
    1.
    发明授权
    Removal promoters and inhibitor for apoptosis cells in vivo 有权

    公开(公告)号：US08603455B2

    公开(公告)日：2013-12-10

    申请号：US12457423

    申请日：2009-06-10

    申请人： Shigekazu Nagata

    发明人： Shigekazu Nagata

    IPC分类号： C07K5/00

    CPC分类号： C07K14/705 ,  A61K38/00

    摘要： The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor.

    Removal promoters and inhibitor for apoptosis cells in vivo
    2.
    发明授权
    Removal promoters and inhibitor for apoptosis cells in vivo 有权
    体内去除启动子和凋亡细胞抑制剂

    公开(公告)号：US08398984B2

    公开(公告)日：2013-03-19

    申请号：US12585997

    申请日：2009-09-30

    申请人： Shigekazu Nagata

    发明人： Shigekazu Nagata

    IPC分类号： A61K39/00 ,  C12P21/08 ,  C07K16/00 ,  C07K16/22 ,  C07K14/00 ,  C07K5/00

    CPC分类号： C07K14/705 ,  A61K38/00

    摘要： The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor.

    摘要翻译： 本发明提供一种能够通过巨噬细胞在体内立即去除凋亡细胞的凋亡细胞去除启动子，或抑制巨噬细胞在体内去除凋亡细胞的去除抑制剂。 含有乳脂肪球-EGF因子8-L（MFG-E8-L），具有由巨噬细胞体内凋亡细胞去除促进作用的MFG-E8-L突变体的凋亡细胞去除启动子，或优选重组人 或小鼠MFG-E8-L，或重组人或小鼠MFG-E8-L突变体作为活性成分。 这种去除启动子特异性结合凋亡细胞，通过识别暴露于凋亡细胞表面的磷脂酰丝氨酸等氨基磷脂，促进巨噬细胞吞噬细胞凋亡。 另一方面，使用点突变（D89E）MFG-E8-L突变体作为去除抑制剂。

    FAS ligand derived polypeptides
    3.
    发明授权
    FAS ligand derived polypeptides 失效
    FAS配体衍生多肽

    公开(公告)号：US07622554B2

    公开(公告)日：2009-11-24

    申请号：US10861934

    申请日：2004-06-07

    申请人： Shigekazu Nagata ,  Takashi Suda ,  Tomohiro Takahashi ,  Norio Nakamura

    发明人： Shigekazu Nagata ,  Takashi Suda ,  Tomohiro Takahashi ,  Norio Nakamura

    IPC分类号： C07K14/475 ,  C12Q1/68 ,  C07H21/04

    CPC分类号： C07K16/2875 ,  C07K14/70575 ,  C07K2319/00

    摘要： This invention provides a polypeptide useful in the field of medicines, a DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the DNA, a transformant transformed with the DNA or the recombinant DNA molecule, a process for the purification of the polypeptide, a process for the production of the polypeptide, an antibody which recognizes the polypeptide, an oligonucleotide complementary to the DNA and a screening method. Particularly this invention provides a polypeptide, which is Fas ligand or a fragment thereof. This polypeptide can be used as an effective ingredient of a medicament for regulating the apoptosis in a living body. This polypeptide is obtained by identifying a DNA fragment, which encodes the polypeptide, transforming a desired host with a recombinant DNA molecule, which contains the DNA fragment, and purifying the polypeptide produced by the resulting transformant. This polypeptide has a cytoplasmic domain, a transmembrane domain and extracellular domain and takes part in apoptosis.

    摘要翻译： 本发明提供了可用于药物领域的多肽，编码新多肽的DNA，含有该DNA的重组DNA分子，用该DNA或重组DNA分子转化的转化体，该多肽的纯化方法， 生产多肽的方法，识别多肽的抗体，与DNA互补的寡核苷酸和筛选方法。 特别地，本发明提供了多肽，其是Fas配体或其片段。 该多肽可以用作调节活体细胞凋亡的药物的有效成分。 通过鉴定编码多肽的DNA片段，用含有DNA片段的重组DNA分子转化所需宿主，并纯化所得转化体产生的多肽来获得该多肽。 该多肽具有胞质结构域，跨膜结构域和细胞外结构域，并参与细胞凋亡。

    Removal promoters and inhibitor for apoptosis cells in vivo
    4.
    发明申请
    Removal promoters and inhibitor for apoptosis cells in vivo 审中-公开

    公开(公告)号：US20060233806A1

    公开(公告)日：2006-10-19

    申请号：US10496087

    申请日：2002-11-19

    申请人： Shigekazu Nagata

    发明人： Shigekazu Nagata

    IPC分类号： A61K39/395 ,  A61K48/00

    摘要： The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor.

    DNA coding for human cell surface antigen
    5.
    发明授权
    DNA coding for human cell surface antigen 失效
    编码人细胞表面抗原的DNA

    公开(公告)号：US06270998B1

    公开(公告)日：2001-08-07

    申请号：US08468560

    申请日：1995-06-06

    申请人： Shigekazu Nagata ,  Naoto Itoh ,  Shin Yonehara

    发明人： Shigekazu Nagata ,  Naoto Itoh ,  Shin Yonehara

    IPC分类号： C12N1512

    CPC分类号： C07K14/715 ,  A61K38/00 ,  C07K16/2878 ,  C07K2317/73

    摘要： DNAs coding for human cell surface antigen (Fas or Fas antigen), vectors for expressing for said DNAs and transformants transfected with said vector are proveded. Fas is a polypeptide that exists in the surfaces of a variety of cells and is considered to be deeply concerned with the apoptosis of cells. The isolated Fas CDNA has an open reading frame that is capable of encoding a protein consisting of 335 amino acids. The mature Fas antigen is a protein consisting of 319 amino acids having a calculated molecular weight of about 36,000 and is constituted by an extracellular domain of 157 amino acids, a membrane-spanning domain of 17 amino acids, and a cytoplasmic domain of 145 amino acids.

    摘要翻译： 证明编码人细胞表面抗原（Fas或Fas抗原）的DNA，用于表达所述DNA的载体和用所述载体转染的转化体。 Fas是存在于多种细胞表面的多肽，被认为与细胞凋亡密切相关。分离的Fas CDNA具有能够编码由335个氨基酸组成的蛋白质的开放阅读框。 成熟的Fas抗原是由319个氨基酸组成的蛋白质，其计算分子量约为36,000，由157个氨基酸的胞外结构域，17个氨基酸的跨膜结构域和145个氨基酸的胞质结构域 。

    DNA fragment and expression plasmid containing the DNA fragment
    7.
    发明授权
    DNA fragment and expression plasmid containing the DNA fragment 失效
    含有DNA片段的DNA片段和表达质粒

    公开(公告)号：US5225348A

    公开(公告)日：1993-07-06

    申请号：US447823

    申请日：1989-12-08

    申请人： Shigekazu Nagata ,  Sumio Sugano ,  Dong W. Kim ,  Taichi Uetsuki ,  Yoshito Kaziro

    发明人： Shigekazu Nagata ,  Sumio Sugano ,  Dong W. Kim ,  Taichi Uetsuki ,  Yoshito Kaziro

    IPC分类号： C12N15/09 ,  C07K14/47 ,  C12N5/10 ,  C12N15/85 ,  C12R1/91

    CPC分类号： C07K14/47 ,  C12N15/85

    摘要： A DNA fragment containing a promoter region for human polypeptide chain elongation factor-1.alpha., its base sequence and expression plasmids containing the DNA fragment having high applicability to a wide range of host cells with high expression capacity. These expression plasmids can be maintained stably for at least one month in mammalian host cells. Such features of the expression plasmids may render possible the efficient production of various kinds of useful physiologically active substances for a long period using wide range of mammalian cells as the host.

    摘要翻译： 含有人多肽链延长因子-1α的启动子区域的DNA片段，其碱基序列和含有该DNA片段的表达质粒具有高度适用于具有高表达能力的多种宿主细胞。 这些表达质粒可以在哺乳动物宿主细胞中稳定保持至少一个月。 使用广泛范围的哺乳动物细胞作为宿主，表达质粒的这些特征可以使长期有效生产各种有用的生理活性物质成为可能。

    DNA encoding Fas ligand
    9.
    发明授权
    DNA encoding Fas ligand 失效
    编码Fas配体的DNA

    公开(公告)号：US06348334B1

    公开(公告)日：2002-02-19

    申请号：US08339214

    申请日：1994-11-10

    申请人： Shigekazu Nagata ,  Takashi Suda ,  Tomohiro Takahashi ,  Norio Nakamura

    发明人： Shigekazu Nagata ,  Takashi Suda ,  Tomohiro Takahashi ,  Norio Nakamura

    IPC分类号： C07H2104

    CPC分类号： C07K14/70575 ,  C07K2319/00

    摘要： This invention provides a novel polypeptide useful in the field of medicines, a novel DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the novel DNA, a transformant transformed with the novel DNA or the recombinant DNA molecule, a process for the purification of the novel polypeptide, a process for the production of the novel polypeptide, an antibody which recognize the novel polypeptide, an oligonucleotide complementary to the novel DNA and a novel screening method. Particularly this invention provides a novel polypeptide which is Fas ligand or a fragment thereof. This novel polypeptide can be used as an effective ingredient of a medicament for regulating the apoptosis in a living body. This novel polypeptide is obtained by identifying a DNA fragment which encodes the novel polpeptide, transforming a desired host with a recombinant DNA molecule which contains the DNA fragment and purifying the novel polypeptide produced by the resulting transformant. This novel polypeptide has a cytoplasmic domain, a transmembrane domain and extracellular domain and takes part in apoptosis.

    摘要翻译： 本发明提供了可用于药物领域的新型多肽，编码新型多肽的新型DNA，含有新DNA的重组DNA分子，用新型DNA或重组DNA分子转化的转化体，纯化方法 的新型多肽的生产方法，识别新多肽的抗体，与新DNA互补的寡核苷酸和新的筛选方法。 特别地，本发明提供了一种新的多肽，其是Fas配体或其片段。 这种新型多肽可以用作调节活体细胞凋亡的药物的有效成分。 通过鉴定编码新型多肽的DNA片段，通过含有该DNA片段的重组DNA分子转化所需宿主并纯化得到的转化体产生的新型多肽来获得该新型多肽。 该新型多肽具有胞质结构域，跨膜结构域和细胞外结构域，并参与细胞凋亡。

    Removal promoters and inhibitor for apoptosis cells in vivo
    10.
    发明申请
    Removal promoters and inhibitor for apoptosis cells in vivo 有权

    公开(公告)号：US20100136100A1

    公开(公告)日：2010-06-03

    申请号：US12457423

    申请日：2009-06-10

    申请人： Shigekazu Nagata

    发明人： Shigekazu Nagata

    IPC分类号： A61K9/127 ,  A61K38/18 ,  A61P43/00

    CPC分类号： C07K14/705 ,  A61K38/00

    摘要： The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor.